Operating Lease, Right-of-Use Asset of AVADEL PHARMACEUTICALS PLC from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
AVADEL PHARMACEUTICALS PLC quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • AVADEL PHARMACEUTICALS PLC Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $2,544,000, a 32% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

AVADEL PHARMACEUTICALS PLC Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,544,000 +$614,000 +32% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $2,721,000 +$567,000 +26% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $2,896,000 +$522,000 +22% 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $1,702,000 -$889,000 -34% 31 Dec 2024 10-Q 04 Nov 2025 2025 Q3
Q3 2024 $1,930,000 -$874,000 -31% 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $2,154,000 +$919,000 +74% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $2,374,000 +$899,000 +61% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $2,591,000 +$878,000 +51% 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $2,804,000 +$857,000 +44% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $1,235,000 -$945,000 -43% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $1,475,000 -$935,000 -39% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $1,713,000 -$939,000 -35% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $1,947,000 -$123,000 -5.9% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $2,180,000 -$69,000 -3.1% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $2,410,000 -$17,000 -0.7% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $2,652,000 +$48,000 +1.8% 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $2,070,000 -$796,000 -28% 30 Sep 2021 10-Q 08 Nov 2021 2021 Q3
Q2 2021 $2,249,000 -$868,000 -28% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $2,427,000 -$938,000 -28% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $2,604,000 -$1,008,000 -28% 31 Dec 2020 10-K 16 Mar 2022 2021 FY
Q3 2020 $2,866,000 -$1,519,000 -35% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $3,117,000 -$2,337,000 -43% 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $3,365,000 -$2,437,000 -42% 31 Mar 2020 10-Q 11 May 2020 2020 Q1
Q4 2019 $3,612,000 +$3,612,000 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $4,385,000 -$1,575,000 -26% 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q2 2019 $5,454,000 +$578,000 +12% 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $5,802,000 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $0 -$2,909,000 -100% 31 Dec 2018 10-K 16 Mar 2020 2019 FY
Q3 2018 $5,960,000 30 Sep 2018 10-Q 05 Nov 2018 2018 Q3
Q2 2018 $4,876,000 30 Jun 2018 10-Q 07 Aug 2018 2018 Q2
Q4 2017 $2,909,000 31 Dec 2017 10-K 15 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.